全文获取类型
收费全文 | 98798篇 |
免费 | 7148篇 |
国内免费 | 4115篇 |
专业分类
耳鼻咽喉 | 419篇 |
儿科学 | 2260篇 |
妇产科学 | 970篇 |
基础医学 | 17829篇 |
口腔科学 | 845篇 |
临床医学 | 7618篇 |
内科学 | 26253篇 |
皮肤病学 | 1177篇 |
神经病学 | 4361篇 |
特种医学 | 1546篇 |
外国民族医学 | 9篇 |
外科学 | 5784篇 |
综合类 | 12361篇 |
现状与发展 | 21篇 |
预防医学 | 11736篇 |
眼科学 | 1254篇 |
药学 | 9015篇 |
23篇 | |
中国医学 | 2595篇 |
肿瘤学 | 3985篇 |
出版年
2023年 | 1044篇 |
2022年 | 2775篇 |
2021年 | 3345篇 |
2020年 | 2834篇 |
2019年 | 3219篇 |
2018年 | 3190篇 |
2017年 | 3060篇 |
2016年 | 3308篇 |
2015年 | 3783篇 |
2014年 | 5793篇 |
2013年 | 6371篇 |
2012年 | 5685篇 |
2011年 | 6434篇 |
2010年 | 5272篇 |
2009年 | 4895篇 |
2008年 | 4690篇 |
2007年 | 5100篇 |
2006年 | 4454篇 |
2005年 | 4007篇 |
2004年 | 3386篇 |
2003年 | 3026篇 |
2002年 | 2500篇 |
2001年 | 2281篇 |
2000年 | 1894篇 |
1999年 | 1733篇 |
1998年 | 1461篇 |
1997年 | 1490篇 |
1996年 | 1134篇 |
1995年 | 1153篇 |
1994年 | 1040篇 |
1993年 | 815篇 |
1992年 | 676篇 |
1991年 | 571篇 |
1990年 | 493篇 |
1989年 | 452篇 |
1988年 | 414篇 |
1987年 | 323篇 |
1986年 | 287篇 |
1985年 | 770篇 |
1984年 | 754篇 |
1983年 | 594篇 |
1982年 | 542篇 |
1981年 | 508篇 |
1980年 | 433篇 |
1979年 | 388篇 |
1978年 | 334篇 |
1977年 | 244篇 |
1976年 | 282篇 |
1975年 | 257篇 |
1974年 | 206篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
3.
4.
5.
目的:探讨老年人桡骨远端C型骨折的手术治疗与非手术治疗的疗效差异,评价两种方法的优缺点。方法回顾性分析2009-12—2011-12收治的老年桡骨远端C型骨折68例,按照治疗方法分为A组(手术组)及B组(非手术组),统计分析两组患者的临床资料。结果 A组33例, B组35例,平均随访21.5个月。两组患者的年龄、骨折类型均无差异(P>0.05);术后影像学指标A组优于B组,骨折愈合时间B组优于A组,治疗成本A组大于B组(P<0.05);Cooney评分早期A组优于B组,1年后两组无差异,两组的并发症无差异(P>0.05)。结论老年人桡骨远端C型骨折手术治疗较非手术治疗可获得更好的复位及早期功能,但远期功能恢复无差异。 相似文献
6.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
7.
《Vaccine》2016,34(26):2948-2952
Herpes simplex virus type-1 (HSV-1) and -2 (HSV-2) are highly prevalent global pathogens which commonly cause recurrent oral and genital ulcerations. Less common but more serious complications include meningitis, encephalitis, neonatal infection, and keratitis. HSV-2 infection is a significant driver of the HIV epidemic, increasing the risk of HIV acquisition 3 fold. As current control strategies for genital HSV-2 infection, including antiviral therapy and condom use, are only partially effective, vaccines will be required to reduce infection. Both preventive and therapeutic vaccines for HSV-2 are being pursued and are in various stages of development. We will provide an overview of efforts to develop HSV-2 vaccines, including a discussion of the clinical need for an HSV vaccine, and status of research and development with an emphasis on recent insights from trials of vaccine candidates in clinical testing. In addition, we will touch upon aspects of HSV vaccine development relevant to low and middle income countries. 相似文献
8.
Frédéric Janvier Deborah Delaune Thomas Poyot Eric Valade Audrey Mérens Pierre E. Rollin Vincent Foissaud 《Emerging infectious diseases》2016,22(2):292-294
We evaluated RNA stability of Ebola virus in EDTA blood and urine samples collected from infected patients and stored in West Africa’s environmental conditions. In blood, RNA was stable for at least 18 days when initial cycle threshold values were <30, but in urine, RNA degradation occurred more quickly. 相似文献
9.
Although hepatitis E virus (HEV) is the primary cause of enterically transmitted acute hepatitis and jaundice in developing countries, locally acquired HEV infections are increasing in nonendemic countries. As such, HEV is emerging as an underdiagnosed cause of infection. This report describes three clinically variable cases of HEV infection with unusual clinical presentations. These cases highlight the fact that HEV should be considered in the differential diagnosis of patients with unexplained hepatitis (acute or chronic) with or without extrahepatic manifestations. HEV should also be considered in patients with persistently elevated liver enzymes who have not travelled to known HEV-endemic regions. Lack of knowledge among physicians and an absence of standardized diagnostic tests may result in increased morbidity and mortality from HEV infection. 相似文献
10.